Abstract:The identification of 16S rDNA biomarkers from respiratory samples to describe the continuum of clinical disease states within persons having cystic fibrosis (CF) has remained elusive. We sought to combine 16S, metagenomics, and metabolomics data to describe multiple transitions between clinical disease states in 14 samples collected over a 12-month period in a single person with CF. We hypothesized that each clinical disease state would have a unique combination of bacterial genera and volatile metabolites as a potential signature that could be utilized as a biomarker of clinical disease state. Taxonomy identified by 16S sequencing corroborated clinical culture results, with the majority of the 109 PCR amplicons belonging to the bacteria grown in clinical cultures (Escherichia coli and Staphylococcus aureus). While alpha diversity measures fluctuated across disease states, no significant trends were present. Principle coordinates analysis showed that treatment samples trended toward a different community composition than baseline and exacerbation samples. This was driven by the phylum Bacteroidetes (less abundant in treatment, log2 fold difference −3.29, p = 0.015) and the genus Stenotrophomonas (more abundant in treatment, log2 fold difference 6.26, p = 0.003). Across all sputum samples, 466 distinct volatile metabolites were identified with total intensity varying across clinical disease state. Baseline and exacerbation samples were rather uniform in chemical composition and similar to one another, while treatment samples were highly variable and differed from the other two disease states. When utilizing a combination of the microbiome and metabolome data, we observed associations between samples dominated Staphylococcus and Escherichia and higher relative abundances of alcohols, while samples dominated by Achromobacter correlated with a metabolomics shift toward more oxidized volatiles. However, the microbiome and metabolome data were not tightly correlated; examining both the metagenomics and metabolomics allows for more context to examine changes across clinical disease states. In our study, combining the sputum microbiome and metabolome data revealed stability in the sputum composition through the first exacerbation and treatment episode, and into the second exacerbation. However, the second treatment ushered in a prolonged period of instability, which after three additional exacerbations and treatments culminated in a new lung microbiome and metabolome.

Ecological patterns and processes of temporal turnover within lung infection microbiota

Changes in Microbiome Dominance Are Associated With Declining Lung Function and Fluctuating Inflammation in People With Cystic Fibrosis

The Lower Airway Microbiome in Paediatric Health and Chronic Disease

Implications for the Microbial Landscape in Cystic Fibrosis

The Longitudinal Microbial and Metabolic Landscape of infant Cystic Fibrosis: The gut-lung axis

Longitudinal Associations of the Cystic Fibrosis Airway Microbiome and Volatile Metabolites: A Case Study

A Polymicrobial Perspective of Pulmonary Infections Exposes an Enigmatic Pathogen in Cystic Fibrosis Patients

The Involvement of the Low-Oxygen-activated Locus of Burkholderia Cenocepacia in Adaptation During Cystic Fibrosis Infection

Intraspecific Diversity of Populations Isolated from Cystic Fibrosis Respiratory Infections

Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations

Widespread alterations in systemic immune profile are linked to lung function heterogeneity and airway microbes in cystic fibrosis

The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease

Polymicrobial Airway Bacterial Communities in Adult Bronchiectasis Patients

Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis

Analysis of the Bacterial Communities Present in Lungs of Patients with Cystic Fibrosis from American and British Centers

16S rRNA gene sequencing reveals site-specific signatures of the upper and lower airways of cystic fibrosis patients

Dynamics of the lung microbiome in intensive care patients with chronic obstructive pulmonary disease and community-acquired pneumonia

The airway microbiome in cystic fibrosis and implications for treatment

Infection and the microbiome in bronchiectasis

Microbiome effects on immunity, health and disease in the lung

Diet and the gut-lung axis in cystic fibrosis – direct & indirect links